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ORIGINAL RESEARCH
Objectives
The aim of the study was to determine the time to, and risk factors for, triple-class virological
failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV
infection and older adolescents and adults with heterosexually acquired HIV infection.
Methods
We analysed individual patient data from cohorts in the Collaboration of Observational HIV
Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral
therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection
and 15–29 years for those with heterosexual infection, with ART containing at least two
nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase
inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the
most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500
HIV-1 RNA copies/mL despite ≥ 4 months of use. TCVF was defined as cumulative failure of two
NRTIs, an NNRTI and a bPI.
Results
The median number of weeks between diagnosis and the start of ART was higher in participants with
perinatal HIV infection compared with participants with heterosexually acquired HIV infection
overall [17 (interquartile range (IQR) 4–111) vs. 8 (IQR 2–38) weeks, respectively], and highest in
perinatally infected participants aged 10–14 years [49 (IQR 9–267) weeks]. The cumulative
proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.012.3%]
in participants with perinatally acquired infection and 4.7% (95% CI 3.95.5%) in participants with
heterosexually acquired infection, and highest in perinatally infected participants aged 10–14 years
when starting ART (27.7%; 95% CI 13.242.1%). Across all participants, significant predictors of
TCVF were those with perinatal HIV aged 10–14 years, African origin, pre-ART AIDS, NNRTI-based
initial regimens, higher pre-ART viral load and lower pre-ART CD4.
Conclusions
The results suggest a beneficial effect of starting ART before adolescence, and starting young
people on boosted PIs, to maximize treatment response during this transitional stage of
development.
Keywords: Europe, perinatal HIV infection, virological failure, young people.
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Introduction
One of the major challenges for children and young peo-
ple with perinatal HIV infection is the maintenance of
long-term adherence to treatment regimens to suppress
virus and prevent resistant virus from developing [1].
Paediatric HIV treatment regimens have relied heavily on
drugs from one or more of the original three antiretrovi-
ral therapy (ART) classes [nucleoside or nucleotide reverse
transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), and
boosted protease inhibitors (bPIs)], as drugs from newer
classes often lack paediatric pharmacokinetic data and
are not approved for use in children (e.g. rilpivirine,
elvitegravir in <18 years of age, dolutegravir in
< 12 years of age), or do not have appropriate paediatric
formulations, and are often expensive [2].
Current European guidelines recommend initiation of
treatment in all infants aged < 1 year, in children
≥ 1 year of age according to age-specific immunological
thresholds (1–3 years, CD4 count ≤ 1000 cells/lL or
CD4% ≤ 25%; 3–5 years, CD4 count ≤ 750 cells/lL or
CD4% ≤ 25%; >5 years, CD4 count ≤ 350 cells/lL), and
in any child with a World Health Organization (WHO)
stage 3/4 or Centers for Disease Control and Prevention
(CDC) category B/C event, largely to prevent progression
to AIDS and death and to potentially optimize the ulti-
mate CD4 count in adulthood [3]. In a previous study, we
showed how the risk of triple-class virological failure
(TCVF) of the three original drug classes in children also
increased with older age at the start of ART [4]. However,
the main analysis of that study used a broad definition of
TCVF which included now outdated treatment regimens,
including unboosted PIs. A restricted analysis (including
two NRTIs with either an NNRTI or a bPI) suggested that
the overall rate of failure in children was over twice as
high as in adults with heterosexually acquired HIV
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infection (hazard ratio 2.2; 95% confidence interval (CI)
1.6, 3.0; P < 0.0001). Here we further explored the differ-
ence in TCVF rates between perinatally infected children
and young adults aged 15 to 29 years with heterosexual
infection, and in particular looked at the effect of age at
the start of ART on risk of TCVF.
Methods
Data were pooled from 22 cohort studies participating in
the Pursuing Later Treatment Options II (PLATO II) pro-
ject in 2010, which is part of the Collaboration of Obser-
vational HIV Epidemiological Research Europe (COHERE)
in EuroCoord (www.cohere.org and www.eurocoord.net),
a collaboration of European cohort studies [5]. This study
included 22 cohort studies with data on heterosexually
infected adults aged 15–29 years, and five cohort studies
with paediatric data on perinatally infected children and
young people aged < 20 years. We chose these age
groups as we wished to compare perinatally HIV-infected
children and teenagers with adults with horizontal infec-
tion who were of a similar age group, and to show how
the risk of TCVF differs across this age spectrum. A com-
parison of younger and older age groups has already
been published elsewhere [6]. The cohort studies included
diagnosed HIV-infected patients attending treatment ser-
vices across Europe, collecting similar data items. Data
submission and quality control procedures have been
described previously [5].
Participants were antiretroviral-na€ıve or had previous
ART exposure for prevention of mother-to-child trans-
mission (PMTCT), and started ART from 1998 onwards
with an initial regimen of two or more NRTIs and either
an NNRTI or a bPI. Follow-up time began at the start of
ART and data were censored at the last reported viral
load measurement. Because the definition of virological
failure used in this study required 4 months of use of a
drug, children were only included if they had at least
4 months (122 days) of follow-up. Time spent off ART
(after ART had been started) was included as follow-up.
Participants were said to be off ART if they stopped all
antiretroviral drugs. Treatment interruption was defined
as cessation of all antiretrovirals for at least 7 days.
The main outcome measure was time to TCVF, defined
as virological failure of at least two NRTI drugs, one
NNRTI drug, and one bPI drug. Virological failure of a
drug was defined as one viral load > 500 HIV-1 RNA
copies/mL following at least 4 months of continuous use
of that drug, regardless of concomitant use of other drugs
in that period. Sensitivity analyses were conducted using
two variations of this virological failure definition: first,
6 months instead of 4 months of continuous drug use;
secondly, viral load > 500 copies/mL after 4 months of
continuous use had to be confirmed by a second viral
load > 500 copies/mL while still on the drug or followed
by discontinuation of the drug.
The date of the first HIV clinic visit was calculated as
the earliest date of: first CD4 count, first viral load mea-
surement, first visit, first diagnosis of an AIDS-defining
condition, or start of ART (including ART for PMTCT).
KaplanMeier and Cox regression methods were used
to investigate the risk of TCVF after starting ART. Poten-
tial predictors of TCVF at the time of starting ART were
sex, age group/risk group, region of origin, year of start-
ing ART, initial regimen, previous ART exposure for
PMTCT, pre-ART AIDS diagnosis, CD4 (a binary measure
combining CD4% <= 25% for patients <5 years of age
and CD4 count <= 350 cells/lL for patients ≥5 years of
age), and viral load (a binary measure, above or below
the median viral load within each age group). In multi-
variable analyses, perinatally HIV-infected young people
aged 15–19 years at the start of ART were excluded
because of their small number (n = 20) and lack of TCVF
events. HIV-related outcomes for those experiencing
TCVF are described.
Analyses were performed using SAS software, version
9.3 (SAS Inc., Cary, NC).
Results
A total of 5972 participants fulfilling the inclusion crite-
ria were identified, and their characteristics at the start of
ART by risk group and age are summarized in Table 1.
Overall, 806 participants (13%) had perinatally acquired
HIV infection, and started ART aged < 20 years, and
5166 participants (87%) acquired HIV heterosexually and
started ART aged 15–29 years. In the 15–19 years age
category, 20 (7%) had perinatally acquired HIV infection
and 264 (93%) had heterosexually acquired HIV infection,
while all those < 15 years of age had perinatally acquired
HIV infection, and all those ≥ 20 years of age had
acquired HIV heterosexually. Initial regimens included
lopinavir/r for 26% of participants with heterosexually
acquired HIV infection and 17% of those with perinatally
acquired HIV infection, efavirenz for 34% of those with
heterosexually acquired HIV infection and 37% of those
with perinatally acquired HIV infection, and nevirapine
for 26% of those with heterosexually acquired HIV infec-
tion and 46% of those with perinatally acquired HIV
infection.
Around half of participants with perinatally acquired
HIV infection and three-quarters of those with heterosex-
ually acquired HIV infection were female, and the major-
ity of most age groups were from sub-Saharan Africa. In
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participants with perinatal HIV infection, the median age
when first seen was 0.5 years [interquartile range (IQR)
0.0–2.7 years] for those born in Europe compared with
5.9 years (IQR 2.4–9.4 years) for those from sub-Saharan
Africa. The median duration between date first seen and
the start of ART varied by risk group and age. It was
around 6-8 weeks for infants with perinatal HIV infection
and participants who acquired HIV infection heterosexu-
ally, but much longer for children with perinatal HIV
infection starting ART at age 5–9 years and 10–14 years
[median 41 (IQR 5–185) and 49 (IQR 9–267) weeks,
respectively], and highest in participants with perinatal
HIV infection starting ART at age 15–19 years, although
numbers were small [median 176 (IQR 55–404); n = 20]
(Table S1).
Median CD4 cell count at the start of ART was lower
in participants with perinatal HIV infection aged 10–14
and 15–19 years than in participants who acquired HIV
heterosexually and also younger patients with perinatal
HIV infection, and, as expected, the median CD4 percent-
age was higher in infants than in other perinatally
infected groups. Similarly, viral load was highest in
Table 1 Characteristics of the 5972 included participants at the start of antiretroviral therapy (ART)
Characteristic
Risk group
Perinatal Heterosexual
Age at start of ART (years)
< 2 2–4 59 1014 1519 1519 2024 2529
Number (%) of
participants
238 (4) 148 (2) 229 (4) 171 (3) 20 (<1) 264 (4) 1459 (24) 3443 (58)
Sex [n (%)]
Male 101 (42) 83 (56) 119 (52) 79 (46) 6 (30) 58 (22) 319 (22) 946 (27)
Female 137 (58) 65 (44) 110 (48) 92 (54) 14 (70) 206 (78) 1140 (78) 2497 (73)
Region of origin [n (%)]
Sub-Saharan
Africa
57 (24) 75 (51) 153 (67) 112 (65) 15 (75) 103 (39) 459 (31) 902 (26)
Europe 169 (71) 61 (41) 62 (27) 50 (29) 5 (25) 35 (13) 277 (19) 708 (21)
Other 11 (5) 12 (8) 13 (6) 8 (5) 0 (0) 6 (10) 195 (13) 536 (16)
Unknown 1 (<1) 0 (0) 1 (<1) 1 (1) 0 (0) 100 (38) 528 (36) 1297 (38)
Pre-ART AIDS [n (%)]
Yes 69 (29) 27 (18) 30 (13) 21 (12) 1 (5) 38 (14) 174 (12) 501 (15)
Time from
diagnosis to
ART start (weeks)
[median (IQR)]
6 (2–18) 24 (5–102) 41 (5–185) 49 (9–267) 176 (55–404) 6 (1–19) 7 (2–33) 8 (2–44)
CD4 count
Median (IQR)
(cells/lL)
1170 (490–1818) 510 (279–793) 281 (160–482) 190 (94–286) 181 (89–231) 262 (163–395) 252 (155–375) 226 (125–325)
Missing [n (%)] 79 (33) 21 (14) 41 (18) 28 (16) 4 (20) 38 (14) 199 (14) 466 (14)
CD4 percentage
Median (IQR) 25 (15–33) 14 (10–19) 13 (9–18) 12 (6–17) – – – –
Missing [n (%)] 81 (34) 20 (14) 48 (21) 31 (18)
Viral load
Median (IQR)
(log10 copies/mL)
5.7 (5.0–5.9) 5.1 (4.7–5.6) 5.0 (4.6–5.3) 4.8 (4.2–5.2) 4.5 (4.2–4.8) 4.8 (3.9–5.2) 4.6 (4.0–5.0) 4.6 (4.0–5.1)
Missing [n (%)] 67 (28) 19 (13) 49 (21) 25 (15) 2 (10) 44 (17) 208 (14) 509 (15)
Year of starting ART [n (%)]
1998–2000 43 (18) 31 (21) 28 (12) 15 (9) 2 (10) 33 (13) 232 (16) 565 (16)
2001–2003 81 (34) 51 (34) 81 (35) 43 (25) 1 (5) 90 (34) 416 (29) 1018 (30)
2004–2006 79 (33) 48 (32) 91 (40) 74 (43) 9 (45) 106 (40) 548 (38) 1261 (37)
2007–2009 35 (15) 18 (12) 29 (13) 39 (23) 8 (40) 35 (13) 263 (18) 599 (17)
Initial regimen [n (%)]
NNRTI +
≥ 2 NRTIs
175 (74) 126 (85) 200 (87) 150 (88) 15 (75) 150 (57) 833 (57) 2107 (61)
bPI + ≥ 2 NRTIs 63 (26) 22 (15) 29 (13) 21 (12) 5 (25) 114 (43) 626 (43) 1336 (39)
PMTCT [n (%)]
Yes 53 (22) 7 (5) 1 (< 1) – – – – –
bPI, boosted protease inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PMTCT, prevention of mother-to-child transmission.
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perinatally infected infants, and lowest at around 4.6
log10 copies/mL in all patients aged ≥ 10 years. Most par-
ticipants started ART between 2000 and 2006. The vast
majority (83%) of patients with perinatal HIV infection
and 60% of those who acquired HIV heterosexually
started on an NNRTI-based regimen.
The overall median follow-up from the start of ART
was 3.5 (IQR 1.7–5.9) years. The median duration of fol-
low-up was markedly lower for participants with perina-
tal HIV infection aged 15–19 years [1.4 (IQR 1.0–2.3)
years]. The rate (95% CI) of treatment interruption was
7.4 (6.5–8.4) per 100 person-years in participants with
perinatal HIV infection and 9.8 (9.4–10.3) per 100 per-
son-years in adults who had acquired HIV heterosexually.
In those who had interrupted treatment, the rate (95% CI)
of restarting was 67.4 (57.2–78.9) per 100 person-years in
participants with perinatal HIV infection and 56.4 (53.5–
59.5) per 100 person-years in those with heterosexually
acquired HIV.
Just under half (357) of participants with perinatal HIV
infection and 1774 of those who acquired HIV heterosex-
ually experienced virological failure. By 5 years after
starting ART, 49.9% (95% CI 45.854.0%) and 41.2%
(95% CI 39.542.8%), respectively, had experienced viro-
logical failure, with no marked differences by age group
(Table S1). By the end of follow-up, 216 of 806 patients
with perinatal HIV infection and 1539 of 5166 patients
with heterosexually acquired HIV had started a third drug
class, and 70 with perinatal HIV infection and 182 with
heterosexually acquired HIV had developed TCVF. The
cumulative proportion of participants experiencing TCVF
by age at the start of ART and risk group is shown in
Table 2 and Figure 1, and was higher in patients with
perinatal HIV infection compared with those with hetero-
sexually acquired HIV overall, and was particularly high
in perinatally infected participants aged 10–14 years, at
27.7% (95% CI 13.2–42.1) by 5 years (Table S1). Of the
252 patients overall with TCVF, 12 (4.8%) had never
attained a viral load ≤ 500 copies/mL.
In a multivariable model (Table 2), after adjustment for
other factors, there was a strong association between age
group and risk group and risk of TCVF. Participants with
perinatal HIV infection aged 10–14 years at ART initia-
tion had a markedly raised risk of failure [hazard ratio
(HR) 5.19; 95% CI 3.11–8.65], participants with perinatal
HIV infection aged < 10 years had an increased risk (e.g.
5–9 years: HR 1.96; 95% CI 1.18–3.25), and those with
heterosexually acquired HIV aged 15–19 years (HR 0.76;
95% CI 0.36–1.65) and 20–24 years (HR 1.36; 95% CI
0.99–1.85) had a similar risk, compared with those with
heterosexually acquired HIV infection aged 25–29 years.
Additionally, participants originating from Europe
compared with sub-Saharan Africa and those starting bPI
regimens compared with NNRTI regimens had a lower
risk, and those with an AIDS diagnosis before starting
ART had a higher risk, as did those with a higher pre-
ART viral load and lower pre-ART CD4. There was no dif-
ference in the risk of failure by sex, ART exposure for
PMTCT in infancy, or year of ART initiation. Sensitivity
analyses conducted using two variations of the virologi-
cal failure definition produced similar results, including
in patients < 2 years of age with perinatal infection.
Clinical outcomes following TCVF are shown in
Table S2. Overall, 1 year after TCVF, CD4 counts were
higher in younger participants with perinatally acquired
HIV infection and those with heterosexually acquired HIV
infection than in participants with perinatal HIV infection
aged 10–14 years, although numbers were small. Simi-
larly, median viral load was higher in perinatally infected
participants aged 10–14 years and lower in all other par-
ticipant groups. Five per cent (three of 64) of participants
with perinatal HIV infection with follow-up data avail-
able after TCVF had been diagnosed with AIDS or died,
compared with 11% (19 of 170) of participants with
heterosexually acquired HIV infection; 9% (six of 64) of
perinatally infected participants compared with 25% (43
of 170) of those with heterosexually acquired HIV infec-
tion had started at least one new drug by 1 year follow-
ing TCVF.
Discussion
In this large collaborative study in which the risk of
TCVF from the start of ART in perinatally HIV-infected
children was directly compared with that in adults with
heterosexually acquired HIV infection, 4.2% developed
TCVF overall. The highest risk of TCVF was in 10-14-
year-old participants with perinatal infection; for this
group, the cumulative incidence of TCVF by 3 years was
nearly 10%, rising sharply to just under 30% by 5 years,
while in all other age groups the proportion at 5 years
was < 9%. This trend was shown in the multivariable
analysis in which the rate of failure in this group was
five times higher than in adults aged 25–29 years with
heterosexually transmitted HIV infection. These results
augment those of our earlier study which described the
rate and predictors of TCVF in children, and which pre-
sented only a very simple analysis comparing rates
between children and adults [4]. Here, we estimated the
differing rates of TCVF across the age spectrum from
infants to young adults, as well as by transmission group.
Participants with perinatally acquired HIV infection
aged 10–14 years had not only the highest rate of TCVF
but also the longest delay in starting ART following HIV
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diagnosis, and the lowest CD4 counts at the start of ART.
Many of these young people were born in sub-Saharan
Africa, some without access to antenatal testing; they
may have complex family issues with a high proportion
being orphans, and HIV symptoms may not have been
recognized, leading to delayed diagnosis [7,8]. Some will
have insecure immigration status which can intensify
concerns about HIV diagnosis and treatment, and disclo-
sure of HIV infection in the family [9,10]. There can also
be issues of coming to terms with their own HIV status,
secrecy and guilt among other family members, and deal-
ing with HIV infection in the context of the adolescent
transitional stage of development [11,12]. Once ART has
been started, studies have found lower rates of viral sup-
pression in young people with perinatal HIV infection
compared with adults [13], which are probably attributa-
ble to adherence issues and poor clinic attendance rather
than drug efficacy, both common problems among young
adults living with other chronic diseases [1, 14–16]. Find-
ings from this study support the benefit of earlier age at
diagnosis where possible, and initiation of ART prior to
the adolescent period, which will probably also favour
improved immunological health [17].
In this study, most participants with perinatal HIV
infection started on an NNRTI-based regimen, while two-
fifths of participants with heterosexually acquired infec-
tion in the study started on bPIs, and those starting with
bPI-based regimens were less likely to develop TCVF. In
our previous study with resistance test data, we found
that most children on an NNRTI regimen had resistance
mutations, but PI resistance was not seen [4]. Resistance
results from the PENPACT-1 trial showed that delaying
switching for those starting a PI-based regimen was a
reasonable strategy, but that more rapid switching from
Table 2 Participants developing triple-class virological failure (TCVF): number, proportion, and predictors from univariable and multivariable
Cox models
Estimated cumulative proportion
developing TCVF by 5 years (%)†
Univariable results Multivariable results
HR 95% CI P-value HR 95% CI P-value
Sex
Male 6.9 (5.2–8.5) 1 – 0.0055 1 – 0.17
Female 4.9 (3.9–5.8) 0.70 0.54–0.90 0.83 0.64–1.09
Age at start of ART and risk group
< 2 years; perinatally acquired 7.8 (3.7–12.0) 1.83 1.11–3.00 <0.0001 2.16 1.25–3.72 <0.0001
2–4 years; perinatally acquired 4.5 (0.6–8.5) 1.67 0.90–3.09 1.45 0.76–2.75
5–9 years; perinatally acquired 8.4 (3.9–12.9) 2.49 1.56–3.96 1.96 1.18–3.25
10–14 years; perinatally acquired 27.7 (13.2–42.1) 6.16 3.81–9.97 5.19 3.11–8.65
15–19 years; heterosexually acquired* 2.1 (0.0–4.1) 0.84 0.39–1.80 0.76 0.36–1.65
20–24 years; heterosexually acquired 5.8 (4.0–7.6) 1.34 0.98–1.82 1.36 0.99–1.85
25–29 years; heterosexually acquired 4.5 (3.5–5.4) 1 – 1 –
Region of origin
Sub-Saharan Africa 6.8 (5.2–8.5) 1 – 0.0003 1 – 0.012
Europe 4.5 (3.0–6.0) 0.56 0.40–0.79 0.59 0.41–0.84
Other/unknown 5.1 (3.9–6.3) 0.61 0.46–0.81 0.79 0.58–1.08
Pre-ART AIDS
No 4.9 (4.0–5.7) 1 0.0044 1 – 0.039
Yes 8.5 (6.1–11.0) 1.55 1.15–2.08 1.38 1.02–1.88
Initial regimen
NNRTI + ≥2 NRTIs 6.1 (5.1–7.1) 1 – 0.0011 1 – 0.0023
bPI + ≥2 NRTIs 3.9 (2.5–5.3) 0.58 0.42–0.80 0.59 0.42–0.83
Pre-ART CD4 composite measure‡
CD4% < 25%/CD4 < 350 cells/lL 6.3 (5.2–7.4) 1 – 0.044 1 – 0.009
CD4% ≥ 25%/CD4 ≥ 350 cells/lL 3.8 (2.3–5.3) 0.74 0.53–1.03 0.85 0.60–1.20
Unknown 4.4 (2.6–6.1) 0.68 0.47–0.99 0.48 0.29–0.77
Pre-ART viral load
Below median for age group 3.3 (2.3–4.3) 1 – 0.0018 1 – 0.0005
Above median for age group 7.0 (5.6–8.3) 1.67 1.26–2.22 1.66 1.24–2.22
Unknown 6.6 (4.4–8.7) 1.47 1.01–2.14 2.13 1.34–3.40
ART, antiretroviral therapy; bPI, boosted protease inhibitor; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
Year of starting ART (unadjusted P = 0.43), previous ART exposure for prevention of mother-to-child transmission (unadjusted P = 0.083) and sex (ad-
justed P = 0.09) were all not significant.
*For the age group 15–19 years, data are shown for participants with heterosexually acquired HIV infection only, as there were only 20 participants
and no events in the 15-19-year age group for participants with perinatally acquired HIV infection.
†KaplanMeier estimates (95% confidence intervals).
‡CD4% for < 5 years; CD4 count for ≥ 5 years.
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an NNRTI-based regimen following virological failure
was needed to avoid accumulation of NRTI resistance
mutations [18]; in this study, these findings would mean
that a higher proportion of the NNRTI group would be at
risk of TCVF. However, results from a large adult trial of
second-line treatment following NNRTI-based first-line
therapy suggested that participants given a PI as second-
line therapy retained NRTI virological activity without
evidence of increased toxicity, even in the presence of
NRTI resistance mutations [19], suggesting that, although
in our study participants met the criteria of TCVF, its
impact may not be substantial.
European guidelines now recommend that if adherence
is questionable, as is often seen in teenagers, a PI-based
regimen should be initiated because of its higher genetic
barrier to resistance [3,20]. Many of the participants with
perinatal HIV infection on PI-based regimens in our study
would have been on lopinavir/r regimens, which are
unpopular among adolescents as they require twice-daily
administration, but now both darunavir and atazanavir
are available to adolescents in once-daily formulations
and have better tolerability. Furthermore, two new once-
daily single-tablet regimens combining integrase inhibi-
tors with an NRTI backbone have recently been licensed
for adults and children aged 12 years and older weighing
at least 35–40 kg and may become a suitable alternative
to PI-based regimens for adolescents [21–25]. Similarly,
innovative treatment strategies designed to improve
adherence are needed for adolescents, and the phase II
BREaks in Adolescent and child THerapy using Efavirenz
and two nRtis (BREATHER) trial recently reported nonin-
feriority of virological suppression in young people on
efavirenz plus two NRTIs having weekends off compared
with continuous therapy; long-term follow-up of these
trial participants has begun [26].
In conclusion, for participants with perinatal HIV
infection, these findings indicate the need to diagnose
and start ART earlier in childhood, and adopt a strategic
approach in ART selection to prevent the emergence of
resistance. These measures may help children and adoles-
cents achieve and sustain virological suppression as they
approach adulthood.
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